Neomycin, but Not Neamine, Blocks Angiogenic Factor Induced Nitric Oxide Release Through Inhibition of Akt Phosphorylation

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Dec 11

PMID 36499606

Authors

Raphael Trouillon

Dong-Ku Kang

Soo-Ik Chang

Danny OHare

Affiliations

Soon will be listed here.

Abstract

Angiogenesis, the growth of new blood vessels, is a critical factor of carcinogenesis. Neomycin and neamine, two drugs blocking the nuclear translocation of angiogenin (ANG), have been proven to inhibit tumour growth in vivo. However, the high toxicity of neomycin prevents its therapeutic use, thus indicating that the less toxic neamine may be a better candidate. Endothelial cells were cultured on a biocompatible multiple microelectrode array (MMA). The release of NO evoked by ANG or vascular endothelial growth factor (VEGF) was detected electrochemically. The effects of neomycin and neamine on ANG- and VEGF-induced NO releases have been investigated. Neomycin totally blocks NO release for concentrations down to the pM range, probably through the inhibition of the Akt kinase phosphorylation, as revealed by confocal microscopy. On the other hand, both ANG- and VEGF-induced NO releases were not significantly hindered by the presence of high concentrations of neamine. The inhibition of the Akt pathway and NO release are expected to lead to a severe decrease in tissue growth and repair, thus indicating a possible cause for the toxicity of neomycin. Furthermore, the data presented here show that ANG- and VEGF-induced NO releases are not dependent on the nuclear translocation of angiogenin, as these events were not abolished by the presence of neamine.

References

Jang S, Kang D, Chang S, Scheraga H, Shin H . High level production of bovine angiogenin in E. coli by an efficient refolding procedure. Biotechnol Lett. 2004; 26(19):1501-4. DOI: 10.1023/B:BILE.0000044452.57375.fb. View

FALCO F, Smith H, Arcieri G . Nephrotoxicity of aminoglycosides and gentamicin. J Infect Dis. 1969; 119(4):406-9. DOI: 10.1093/infdis/119.4-5.406. View

Joannides R, Haefeli W, Linder L, Richard V, Bakkali E, Thuillez C . Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation. 1995; 91(5):1314-9. DOI: 10.1161/01.cir.91.5.1314. View

Shapiro R, Vallee B . Human placental ribonuclease inhibitor abolishes both angiogenic and ribonucleolytic activities of angiogenin. Proc Natl Acad Sci U S A. 1987; 84(8):2238-41. PMC: 304624. DOI: 10.1073/pnas.84.8.2238. View

Hu G, Xu C, Riordan J . Human angiogenin is rapidly translocated to the nucleus of human umbilical vein endothelial cells and binds to DNA. J Cell Biochem. 2000; 76(3):452-62. DOI: 10.1002/(sici)1097-4644(20000301)76:3<452::aid-jcb12>3.0.co;2-z. View

Leung D, Cachianes G, Kuang W, Goeddel D, Ferrara N . Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989; 246(4935):1306-9. DOI: 10.1126/science.2479986. View

Trouillon R, Williamson E, Saint R, OHare D . Electrochemical detection of the binding of Bacillus anthracis protective antigen (PA) to the membrane receptor on macrophages through release of nitric oxide. Biosens Bioelectron. 2012; 38(1):138-44. DOI: 10.1016/j.bios.2012.05.012. View

Hirukawa S, Olson K, Tsuji T, Hu G . Neamine inhibits xenografic human tumor growth and angiogenesis in athymic mice. Clin Cancer Res. 2005; 11(24 Pt 1):8745-52. DOI: 10.1158/1078-0432.CCR-05-1495. View

Moncada S, Palmer R, Higgs E . Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991; 43(2):109-42. View

10.

Warboys C, Eric Berson R, Mann G, Pearson J, Weinberg P . Acute and chronic exposure to shear stress have opposite effects on endothelial permeability to macromolecules. Am J Physiol Heart Circ Physiol. 2010; 298(6):H1850-6. PMC: 2886649. DOI: 10.1152/ajpheart.00114.2010. View

11.

Kishimoto K, Liu S, Tsuji T, Olson K, Hu G . Endogenous angiogenin in endothelial cells is a general requirement for cell proliferation and angiogenesis. Oncogene. 2004; 24(3):445-56. DOI: 10.1038/sj.onc.1208223. View

12.

Hockel M, Vaupel P . Biological consequences of tumor hypoxia. Semin Oncol. 2001; 28(2 Suppl 8):36-41. View

13.

Bogdan C . Nitric oxide and the immune response. Nat Immunol. 2001; 2(10):907-16. DOI: 10.1038/ni1001-907. View

14.

Madrid L, Wang C, Guttridge D, Schottelius A, Baldwin Jr A, Mayo M . Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappaB. Mol Cell Biol. 2000; 20(5):1626-38. PMC: 85346. DOI: 10.1128/MCB.20.5.1626-1638.2000. View

15.

Michell B, Griffiths J, Mitchelhill K, Rodriguez-Crespo I, Tiganis T, Bozinovski S . The Akt kinase signals directly to endothelial nitric oxide synthase. Curr Biol. 1999; 9(15):845-8. DOI: 10.1016/s0960-9822(99)80371-6. View

16.

Chen C, Shapiro R . Site-specific mutagenesis reveals differences in the structural bases for tight binding of RNase inhibitor to angiogenin and RNase A. Proc Natl Acad Sci U S A. 1997; 94(5):1761-6. PMC: 19990. DOI: 10.1073/pnas.94.5.1761. View

17.

Weidner N, Semple J, Welch W, Folkman J . Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med. 1991; 324(1):1-8. DOI: 10.1056/NEJM199101033240101. View

18.

Batchelor T, Duda D, Tomaso E, Ancukiewicz M, Plotkin S, Gerstner E . Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010; 28(17):2817-23. PMC: 2903316. DOI: 10.1200/JCO.2009.26.3988. View

19.

Trouillon R . Biological applications of the electrochemical sensing of nitric oxide: fundamentals and recent developments. Biol Chem. 2012; 394(1):17-33. DOI: 10.1515/hsz-2012-0245. View

20.

Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P . Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996; 56(19):4509-15. View